antigen immunoglobulin A. Tests were 2-sided, and a P value <.05 was considered significant. Results The characteristics of the 2,263 patients in the different treatment groups are presented in Table 1 . In the NACT + CCRT group (N=1,073), 81.5% of
Search Results
Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai
Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, and Pierre I. Karakiewicz
.29). 14 , 18 Only patients with a secondary diagnosis of metastatic disease were included (ICD-9-CM codes 197.x and 198.x). These selection criteria yielded 1,944 patients. Patient and Hospital Characteristics Patient age at admission, year of admission
Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi
. Statistical analysis was performed using SPSS Statistics, version 25 (IBM Corporation), and P <.05 was considered statistically significant. Results A total of 153 patients were included in the analysis; baseline characteristics are shown in Table 1 . Median
Seyed M. Qaderi, Paul W. Dickman, Johannes H.W. de Wilt, and Rob H.A. Verhoeven
data from the Netherlands Cancer Registry (NCR). 13 All patients newly diagnosed with cancer are registered in the nationwide NCR. Information regarding patient and tumor characteristics are extracted directly from medical records by trained NCR data
Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir
,586). Results Cohort Characteristics A total of 22,033 patients were included in the cohort with a mean age of 75 years. Prior diagnosis of osteoporosis and use of bisphosphonates were found in 1.2% and 6.3% of the cohort, respectively. Most patients were
Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna
accessible online at http://www.cdc.gov/nchs/nhds.htm . All diagnoses are based on ICD-9-CM codes. Data Collection Data collected and analyzed included age, sex, race, admission type (urgent/emergent vs elective), hospital characteristics, LOS
Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill
patients who underwent SCS by imaging practices. Characteristics between patients treated by high- versus low-frequency imaging providers were compared using chi-square tests for discrete variables and t tests for continuous variables. Because CA-125
Areej El-Jawahri, Deborah Forst, Alyssa Fenech, Keri O. Brenner, Amanda L. Jankowski, Lauren Waldman, Isabella Sereno, Ryan Nipp, Joseph A. Greer, Lara Traeger, Vicki Jackson, and Jennifer Temel
, relationship status, or time since diagnosis of incurable cancer and patient-reported QoL or mood. Table 1. Participant Characteristics Patients’ Perceptions of Both Their Treatment Goal and Their Oncologist’s Goal Figure 1 depicts patients’ perceptions of
Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang
excluded if they received no therapy or if their database records were missing values for therapy or type of surgery. Baseline patient demographics (age and sex), tumor characteristics (histologic grade, cell type, T stage), and treatment details (surgery
Rongbo Lin, Jinfeng Zhu, Yushuang Luo, Xia Lv, Mingqian Lu, Haihui Chen, Huichao Zou, Zhichun Zhang, Shaowei Lin, Milu Wu, Xiaofeng Li, Min Zhou, Shen Zhao, Liyu Su, Jiang Liu, and Cheng Huang
or avNRS among the 3 arms ( Table 1 ). Other baseline characteristics were well balanced between the 3 groups, with comparable ESAS symptom severity ( supplemental eTable 2 and Table 1 ). Figure 1. Study profile. (A1) Bolus-only arm, (A2